Structural and functional properties of SARS-CoV-2 spike protein: potential antivirus drug development for COVID-19 (Q98196753)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:32747721%20AND%20SRC:MED&resulttype=core&format=json

10 August 2020

2 references

13 July 2022

22 October 2022

Structural and functional properties of SARS-CoV-2 spike protein: potential antivirus drug development for COVID-19 (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:32747721%20AND%20SRC:MED&resulttype=core&format=json

10 August 2020

1 reference

1 reference

spike glycoprotein [SARS-CoV-2]

1 reference

based on heuristic

inferred from abstract

structural biology

1 reference

based on heuristic

inferred from abstract

author name string

Yuan Huang

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:32747721%20AND%20SRC:MED&resulttype=core&format=json

10 August 2020

Chan Yang

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:32747721%20AND%20SRC:MED&resulttype=core&format=json

10 August 2020

Xin-Feng Xu

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:32747721%20AND%20SRC:MED&resulttype=core&format=json

10 August 2020

Wei Xu

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:32747721%20AND%20SRC:MED&resulttype=core&format=json

10 August 2020

Shu-Wen Liu

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:32747721%20AND%20SRC:MED&resulttype=core&format=json

10 August 2020

publication date

3 August 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:32747721%20AND%20SRC:MED&resulttype=core&format=json

Acta Pharmacologica Sinica

10 August 2020

1 September 2020

2 references

13 July 2022

22 October 2022

3 references

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:32747721%20AND%20SRC:MED&resulttype=core&format=json

10 August 2020

13 July 2022

22 October 2022

A Novel Coronavirus from Patients with Pneumonia in China, 2019

1 reference

https://api.crossref.org/works/10.1038/S41401-020-0485-4

Analysis of therapeutic targets for SARS-CoV-2 and discovery of potential drugs by computational methods

26 December 2020

1 reference

https://api.crossref.org/works/10.1038/S41401-020-0485-4

Research and Development on Therapeutic Agents and Vaccines for COVID-19 and Related Human Coronavirus Diseases

26 December 2020

1 reference

https://api.crossref.org/works/10.1038/S41401-020-0485-4

Connecting With Patients-The Missing Links

26 December 2020

1 reference

https://api.crossref.org/works/10.1038/S41401-020-0485-4

Genomic characterisation and epidemiology of 2019 novel coronavirus: implications for virus origins and receptor binding

26 December 2020

1 reference

https://api.crossref.org/works/10.1038/S41401-020-0485-4

RNA based mNGS approach identifies a novel human coronavirus from two individual pneumonia cases in 2019 Wuhan outbreak

26 December 2020

1 reference

https://api.crossref.org/works/10.1038/S41401-020-0485-4

Genomic characterization of the 2019 novel human-pathogenic coronavirus isolated from a patient with atypical pneumonia after visiting Wuhan

26 December 2020

1 reference

https://api.crossref.org/works/10.1038/S41401-020-0485-4

Functional assessment of cell entry and receptor usage for SARS-CoV-2 and other lineage B betacoronaviruses

26 December 2020

1 reference

https://api.crossref.org/works/10.1038/S41401-020-0485-4

Coronaviruses: an overview of their replication and pathogenesis.

26 December 2020

1 reference

https://api.crossref.org/works/10.1038/S41401-020-0485-4

Learning from the Past: Possible Urgent Prevention and Treatment Options for Severe Acute Respiratory Infections Caused by 2019-nCoV

26 December 2020

1 reference

https://api.crossref.org/works/10.1038/S41401-020-0485-4

The Coronavirus Spike Protein Is a Class I Virus Fusion Protein: Structural and Functional Characterization of the Fusion Core Complex

26 December 2020

1 reference

https://api.crossref.org/works/10.1038/S41401-020-0485-4

Fusion mechanism of 2019-nCoV and fusion inhibitors targeting HR1 domain in spike protein

26 December 2020

1 reference

https://api.crossref.org/works/10.1038/S41401-020-0485-4

Coronavirus membrane fusion mechanism offers as a potential target for antiviral development

26 December 2020

1 reference

https://api.crossref.org/works/10.1038/S41401-020-0485-4

Cryo-EM structure of the 2019-nCoV spike in the prefusion conformation

26 December 2020

1 reference

https://api.crossref.org/works/10.1038/S41401-020-0485-4

Structure, Function, and Antigenicity of the SARS-CoV-2 Spike Glycoprotein

26 December 2020

1 reference

https://api.crossref.org/works/10.1038/S41401-020-0485-4

TMPRSS2 activates the human coronavirus 229E for cathepsin-independent host cell entry and is expressed in viral target cells in the respiratory epithelium

26 December 2020

1 reference

https://api.crossref.org/works/10.1038/S41401-020-0485-4

SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor

26 December 2020

1 reference

https://api.crossref.org/works/10.1038/S41401-020-0485-4

Cleavage of spike protein of SARS coronavirus by protease factor Xa is associated with viral infectivity

26 December 2020

1 reference

https://api.crossref.org/works/10.1038/S41401-020-0485-4

Structural and Functional Basis of SARS-CoV-2 Entry by Using Human ACE2

26 December 2020

1 reference

https://api.crossref.org/works/10.1038/S41401-020-0485-4

Structure of the SARS-CoV-2 spike receptor-binding domain bound to the ACE2 receptor

26 December 2020

1 reference

https://api.crossref.org/works/10.1038/S41401-020-0485-4

A pan-coronavirus fusion inhibitor targeting the HR1 domain of human coronavirus spike

26 December 2020

1 reference

https://api.crossref.org/works/10.1038/S41401-020-0485-4

Physiological and molecular triggers for SARS-CoV membrane fusion and entry into host cells.

26 December 2020

1 reference

https://api.crossref.org/works/10.1038/S41401-020-0485-4

Heptad repeat sequences are located adjacent to hydrophobic regions in several types of virus fusion glycoproteins

26 December 2020

1 reference

https://api.crossref.org/works/10.1038/S41401-020-0485-4

Computers and viral diseases. Preliminary bioinformatics studies on the design of a synthetic vaccine and a preventative peptidomimetic antagonist against the SARS-CoV-2 (2019-nCoV, COVID-19) coronavirus

26 December 2020

1 reference

https://api.crossref.org/works/10.1038/S41401-020-0485-4

Peptide-Based Membrane Fusion Inhibitors Targeting HCoV-229E Spike Protein HR1 and HR2 Domains.

26 December 2020

1 reference

https://api.crossref.org/works/10.1038/S41401-020-0485-4

Bat-to-human: spike features determining 'host jump' of coronaviruses SARS-CoV, MERS-CoV, and beyond

26 December 2020

1 reference

https://api.crossref.org/works/10.1038/S41401-020-0485-4

Interaction between heptad repeat 1 and 2 regions in spike protein of SARS-associated coronavirus: implications for virus fusogenic mechanism and identification of fusion inhibitors

26 December 2020

1 reference

https://api.crossref.org/works/10.1038/S41401-020-0485-4

Structural basis for membrane fusion by enveloped viruses

26 December 2020

1 reference

https://api.crossref.org/works/10.1038/S41401-020-0485-4

Cryo-electron microscopy structures of the SARS-CoV spike glycoprotein reveal a prerequisite conformational state for receptor binding

26 December 2020

1 reference

https://api.crossref.org/works/10.1038/S41401-020-0485-4

Coronavirus Spike Protein and Tropism Changes

26 December 2020

1 reference

https://api.crossref.org/works/10.1038/S41401-020-0485-4

Structural basis for the recognition of the SARS-CoV-2 by full-length human ACE2

26 December 2020

1 reference

https://api.crossref.org/works/10.1038/S41401-020-0485-4

Origin and evolution of pathogenic coronaviruses

26 December 2020

1 reference

https://api.crossref.org/works/10.1038/S41401-020-0485-4

A novel angiotensin-converting enzyme-related carboxypeptidase (ACE2) converts angiotensin I to angiotensin 1-9

26 December 2020

1 reference

https://api.crossref.org/works/10.1038/S41401-020-0485-4

Angiotensin-converting enzyme 2 (ACE2) as a SARS-CoV-2 receptor: molecular mechanisms and potential therapeutic target

26 December 2020

1 reference

https://api.crossref.org/works/10.1038/S41401-020-0485-4

Cell entry mechanisms of SARS-CoV-2

26 December 2020

1 reference

https://api.crossref.org/works/10.1038/S41401-020-0485-4

Structure analysis of the receptor binding of 2019-nCoV

26 December 2020

1 reference

https://api.crossref.org/works/10.1038/S41401-020-0485-4

Structural basis for human coronavirus attachment to sialic acid receptors

26 December 2020

1 reference

https://api.crossref.org/works/10.1038/S41401-020-0485-4

The spike glycoprotein of the new coronavirus 2019-nCoV contains a furin-like cleavage site absent in CoV of the same clade

26 December 2020

1 reference

https://api.crossref.org/works/10.1038/S41401-020-0485-4

A review on the cleavage priming of the spike protein on coronavirus by angiotensin-converting enzyme-2 and furin

26 December 2020

1 reference

https://api.crossref.org/works/10.1038/S41401-020-0485-4

Host cell proteases: Critical determinants of coronavirus tropism and pathogenesis

26 December 2020

1 reference

https://api.crossref.org/works/10.1038/S41401-020-0485-4

Human influenza A H5N1 virus related to a highly pathogenic avian influenza virus

26 December 2020

1 reference

https://api.crossref.org/works/10.1038/S41401-020-0485-4

Role of host cellular proteases in the pathogenesis of influenza and influenza-induced multiple organ failure

26 December 2020

1 reference

https://api.crossref.org/works/10.1038/S41401-020-0485-4

TMPRSS2 and ADAM17 cleave ACE2 differentially and only proteolysis by TMPRSS2 augments entry driven by the severe acute respiratory syndrome coronavirus spike protein

26 December 2020

1 reference

https://api.crossref.org/works/10.1038/S41401-020-0485-4

TMPRSS2 Is the Major Activating Protease of Influenza A Virus in Primary Human Airway Cells and Influenza B Virus in Human Type II Pneumocytes

26 December 2020

1 reference

https://api.crossref.org/works/10.1038/S41401-020-0485-4

Biochemical Analysis of Coronavirus Spike Glycoprotein Conformational Intermediates during Membrane Fusion

26 December 2020

1 reference

https://api.crossref.org/works/10.1038/S41401-020-0485-4

26 December 2020

1 reference

https://api.crossref.org/works/10.1038/S41401-020-0485-4

Mechanisms of viral membrane fusion and its inhibition

26 December 2020

1 reference

https://api.crossref.org/works/10.1038/S41401-020-0485-4

COVID-19, an emerging coronavirus infection: advances and prospects in designing and developing vaccines, immunotherapeutics, and therapeutics

26 December 2020

1 reference

https://api.crossref.org/works/10.1038/S41401-020-0485-4

Novel antibody epitopes dominate the antigenicity of spike glycoprotein in SARS-CoV-2 compared to SARS-CoV

26 December 2020

1 reference

https://api.crossref.org/works/10.1038/S41401-020-0485-4

Rapid development of an inactivated vaccine candidate for SARS-CoV-2

26 December 2020

1 reference

https://api.crossref.org/works/10.1038/S41401-020-0485-4

Purified coronavirus spike protein nanoparticles induce coronavirus neutralizing antibodies in mice

26 December 2020

1 reference

https://api.crossref.org/works/10.1038/S41401-020-0485-4

Potent binding of 2019 novel coronavirus spike protein by a SARS coronavirus-specific human monoclonal antibody

26 December 2020

1 reference

https://api.crossref.org/works/10.1038/S41401-020-0485-4

Human monoclonal antibodies block the binding of SARS-CoV-2 spike protein to angiotensin converting enzyme 2 receptor

26 December 2020

1 reference

https://api.crossref.org/works/10.1038/S41401-020-0485-4

Fully human single-domain antibodies against SARS-CoV-2

26 December 2020

1 reference

https://api.crossref.org/works/10.1038/S41401-020-0485-4

Structural and functional analysis of a potent sarbecovirus neutralizing antibody

26 December 2020

1 reference

https://api.crossref.org/works/10.1038/S41401-020-0485-4

Potent human neutralizing antibodies elicited by SARS-CoV-2 infection

26 December 2020

1 reference

https://api.crossref.org/works/10.1038/S41401-020-0485-4

A potent neutralizing human antibody reveals the N-terminal domain of the Spike protein of SARS-CoV-2 as a site of vulnerability

26 December 2020

1 reference

https://api.crossref.org/works/10.1038/S41401-020-0485-4

Inhibition of SARS-CoV-2 (previously 2019-nCoV) infection by a highly potent pan-coronavirus fusion inhibitor targeting its spike protein that harbors a high capacity to mediate membrane fusion

26 December 2020

1 reference

https://api.crossref.org/works/10.1038/S41401-020-0485-4

The anti-HIV Drug Nelfinavir Mesylate (Viracept) is a Potent Inhibitor of Cell Fusion Caused by the SARS-CoV-2 Spike (S) Glycoprotein Warranting further Evaluation as an Antiviral against COVID-19 infections

26 December 2020

1 reference

https://api.crossref.org/works/10.1038/S41401-020-0485-4

Camostat mesilate therapy for COVID-19

26 December 2020

1 reference

https://api.crossref.org/works/10.1038/S41401-020-0485-4

Alisporivir inhibits MERS- and SARS-coronavirus replication in cell culture, but not SARS-coronavirus infection in a mouse model

26 December 2020

1 reference

https://api.crossref.org/works/10.1038/S41401-020-0485-4

Glycopeptide Antibiotics Potently Inhibit Cathepsin L in the Late Endosome/Lysosome and Block the Entry of Ebola Virus, Middle East Respiratory Syndrome Coronavirus (MERS-CoV), and Severe Acute Respiratory Syndrome Coronavirus (SARS-CoV).

26 December 2020

1 reference

https://api.crossref.org/works/10.1038/S41401-020-0485-4

The phosphatidylinositol-3-phosphate 5-kinase inhibitor apilimod blocks filoviral entry and infection

26 December 2020

1 reference

https://api.crossref.org/works/10.1038/S41401-020-0485-4

Ebola virus. Two-pore channels control Ebola virus host cell entry and are drug targets for disease treatment

26 December 2020

1 reference

https://api.crossref.org/works/10.1038/S41401-020-0485-4

Proprotein convertases in health and disease

26 December 2020

1 reference

https://api.crossref.org/works/10.1038/S41401-020-0485-4

Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China

26 December 2020

1 reference

https://api.crossref.org/works/10.1038/S41401-020-0485-4

FURIN Inhibition Reduces Vascular Remodeling and Atherosclerotic Lesion Progression in Mice

26 December 2020

1 reference

https://api.crossref.org/works/10.1038/S41401-020-0485-4

The serpin proteinase inhibitor 8: an endogenous furin inhibitor released from human platelets

26 December 2020

1 reference

https://api.crossref.org/works/10.1038/S41401-020-0485-4

Peptidomimetic furin inhibitor MI-701 in combination with oseltamivir and ribavirin efficiently blocks propagation of highly pathogenic avian influenza viruses and delays high level oseltamivir resistance in MDCK cells

26 December 2020

1 reference

https://api.crossref.org/works/10.1038/S41401-020-0485-4

Alteration of brain network topology in HIV-associated neurocognitive disorder: A novel functional connectivity perspective.

26 December 2020

1 reference

https://api.crossref.org/works/10.1038/S41401-020-0485-4

The establishment of reference sequence for SARS-CoV-2 and variation analysis

26 December 2020

1 reference

https://api.crossref.org/works/10.1038/S41401-020-0485-4

Perspectives on therapeutic neutralizing antibodies against the Novel Coronavirus SARS-CoV-2

26 December 2020

1 reference

https://api.crossref.org/works/10.1038/S41401-020-0485-4

Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro

26 December 2020

1 reference

https://api.crossref.org/works/10.1038/S41401-020-0485-4

A neutralizing human antibody binds to the N-terminal domain of the Spike protein of SARS-CoV-2

26 December 2020

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=7396720

Identification of Human Single-Domain Antibodies against SARS-CoV-2

10 February 2021

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=7396720

Design of potent membrane fusion inhibitors against SARS-CoV-2, an emerging coronavirus with high fusogenic activity

10 February 2021

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=7396720

SARS-CoV-2 viral spike G614 mutation exhibits higher case fatality rate

10 February 2021

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=7396720

A human monoclonal antibody blocking SARS-CoV-2 infection

10 February 2021

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=7396720

Site-specific glycan analysis of the SARS-CoV-2 spike

10 February 2021

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=7396720

Pharmacologic Treatments for Coronavirus Disease 2019 (COVID-19): A Review

10 February 2021

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=7396720

SARS-CoV-2, SARS-CoV, and MERS-COV: A comparative overview

10 February 2021

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=7396720

Characterization of spike glycoprotein of SARS-CoV-2 on virus entry and its immune cross-reactivity with SARS-CoV

10 February 2021

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=7396720

Receptor Recognition by the Novel Coronavirus from Wuhan: an Analysis Based on Decade-Long Structural Studies of SARS Coronavirus

10 February 2021

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=7396720

Inhibition of PIKfyve using YM201636 suppresses the growth of liver cancer via the induction of autophagy

10 February 2021

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=7396720

Furin inhibitor D6R suppresses epithelial-mesenchymal transition in SW1990 and PaTu8988 cells via the Hippo-YAP signaling pathway

10 February 2021

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=7396720

A peptide-based viral inactivator inhibits Zika virus infection in pregnant mice and fetuses

10 February 2021

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=7396720

SARS-CoV, but not HCoV-NL63, utilizes cathepsins to infect cells: viral entry

10 February 2021

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=7396720

10.1038/S41401-020-0485-4

10 February 2021

Identifiers

DOI

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:32747721%20AND%20SRC:MED&resulttype=core&format=json

10 August 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:32747721%20AND%20SRC:MED&resulttype=core&format=json

10 August 2020

PubMed publication ID

32747721

1 reference